INTRODUCTION
============

Cell therapy represents a novel therapeutic strategy for treating cardiovascular diseases including ischemic heart disease (IHD) and heart failure.[@b1-cln63_2p0207],[@b2-cln63_2p0207] It is widely accepted that bone marrow-derived cells (BMC) can play a role in the induction of angiogenesis under different conditions such as wound healing and limb ischemia,[@b3-cln63_2p0207],[@b4-cln63_2p0207] post-myocardial infarction,[@b5-cln63_2p0207],[@b6-cln63_2p0207] and endothelization of vascular grafts.[@b7-cln63_2p0207] Results from animal models of IHD have shown that pluripotent stem cells have the potential to differentiate in both contractile and blood vessels in ischemic tissues.[@b8-cln63_2p0207],[@b9-cln63_2p0207] Early reports of improvement in myocardial perfusion and segmental contractility either for acute[@b10-cln63_2p0207] or chronic[@b11-cln63_2p0207] IHD in small series of patients have established the feasibility and short-term safety of transplantation of BMC in IHD.

Still, the long-term safety profile of BMC in the clinical setting is subject to several major concerns.[@b12-cln63_2p0207] Since BMC consist of a heterogeneous population of undifferentiated cells able to differentiate into various cell types by means of a complex and poorly understood process, it is possible that unintended cell differentiation towards non-cardiac tissues may occur[@b13-cln63_2p0207] as well as oncogenic transformation.[@b14-cln63_2p0207]. Uncontrolled vascular growth has been demonstrated in transgenic animals expressing increased levels of angiogenic cytok-ines,[@b15-cln63_2p0207] a finding inspiring caution since BMC can express different angiogenic factors.[@b16-cln63_2p0207] Based on previous data on the use of myoblasts in cell therapy trials, malignant ventricular arrhythmias have been documented with potentially serious consequences.[@b17-cln63_2p0207],[@b18-cln63_2p0207] These safety issues must be carefully addressed before progressing to efficacy studies with a larger number of patients.

Accordingly, the present study was designed to test the hypothesis that, in the long-term, intramyocardial injection of autologous BMC is feasible, safe and well-tolerated. Furthermore, this injection may serve as an adjunctive therapy to patients undergoing surgical myocardial revascularization for severe IHD and diffuse coronary artery disease (CAD), helping to increase myocardial perfusion and contractility.

METHODS
=======

This prospective, non-randomized, open-label, phase I clinical study was approved by the Institutional Ethics Committee and was conducted in accordance with federal guidelines of the Brazilian National Research Ethics Council (CONEP).

Patient Selection
-----------------

From August 2002 to July 2003, ten patients were referred to the Cell Therapy Group for Chronic Ischemic Heart Disease at the Heart Institute (InCor) for clinical evaluation. They were included in this safety trial based on the following criteria: the age was between 18 and 80 years; limiting angina was present (Class III--IV as defined by the Canadian Cardiovascular Society[@b19-cln63_2p0207] despite maximally tolerated medical therapy); multi-vessel CAD was present; patients were non-optimal candidates for a "complete" bypass surgery due to the extension and severity of the obstructive lesions according to an expert panel; and patients had at least one non-bypassable coronary artery associated with an area of viable, ischemic myocardium. Patients were excluded if any of the following criteria was met: life expectancy less than one year; past or current history of neoplasia; no objective evidence of myocardial ischemia; primary hematological disease; or associated cardiomyopathy of other etiologies. All patients provided a signed, written informed consent. [Table 1](#t1-cln63_2p0207){ref-type="table"} shows the clinical characteristics of enrolled patients.

Study Protocol
--------------

At baseline (B), and at 1, 3, 6, and 12 months after the procedure, all patients were subjected to a clinical evaluation, laboratory tests, 24-h Holter monitoring, and echocardiogram. Also, myocardial perfusion was blindly assessed by magnetic resonance imaging (MRI). After the first year, patients were followed on a clinical basis only. A five-year follow-up re-evaluation is currently being performed.

### • 24-h Holter Monitoring

ECG Holter monitoring was performed with Marquette 800 portable amplitude-modulated two-channel devices (Marquette 9428; Marquette Medical Systems, Milwaukee, WI). After the monitor was withdrawn, the tapes were analyzed with the MARS system (Marquette). Maximum, minimum, and mean heart rate values were determined, and the occurrence of arrhythmias was recorded.

### • Echocardiogram

Echocardiogram examinations were performed by two-dimensional (2-D) imaging and by spectral and color flow mapping with a 2.75-MHz transducer or a 2--4-MHz/3--5-MHz phased array transducer as previously described[@b20-cln63_2p0207] with an Apogee CX 200 ultrasound system (Interspec, Inc, Ambler, PA), or with an HDI 3000/5000 device (Advanced Technology Laboratories, Bothell, WA). The left ventricle (LV) ejection fraction was determined by the 2-D mode from the apical view (4- and 2-chamber), according to Simpson's rule.

### • Magnetic Resonance Imaging (MRI)

All patients underwent MRI examination in a 1.5T MR scanner (GE CV/i System, GE Medical Systems, Wakesha, WI). First-pass myocardial perfusion LV short-axis images were obtained 3 min after dipyridamole injection (0.56mg. kg^−1^ injected over 4 min). After dynamic MR images acquisition was started, 0.05mM.kg^−1^ of gadolinium-based contrast material (gadodiamide, Ominiscan™, Amersham Health, Princeton, NJ) was injected into the antecubital vein by a power injector at a rate of 5mL.s^−1^ and followed by a 20-mL saline flush. Immediately after this stress perfusion sequence, aminophyline was intravenously injected. Myocardial perfusion was blindly determined in 17 myocardial segments; each segment was graded as normal perfusion (score 0), or having mild (score 1) or severe (score 2) perfusion defects. An overall ischemic score based on all 17 segments (total ischemic score) or only segments injected with BMC (regional ischemic score) was calculated.

#### Preparation of the BMC

After induction of anesthesia and immediately prior to surgery, 100 mL of bone marrow from the right posterior iliac crest were aspirated and heparinized. Bone marrow--derived progenitor and mononuclear cells were isolated by density gradient centrifugation on Ficoll-Paque Plus™ (Amersham Biosciences Corp., Piscataway, NJ), washed with heparinized saline, resuspended in 5mL normal saline, and placed in five 1-mL syringes ready for injection. A 1-mL sample of the cell suspension was used for cell counting and sorting by flow cytometry using leukocyte differentiation markers. A trypan blue exclusion test showed viability greater than 90%.

### • Flow Cytometry Analysis

The cell sample consisted of a heterogeneous cell population with bone marrow--derived progenitor and mononuclear cells. The samples were treated with human IgG polyclonal antibody and incubated with the different monoclonal antibodies conjugated with fluorescein isothiocyanate (Pharmingen, San Diego, CA), phycoerythrin (PE), PerCP or CyChrome as shown in [Table 2](#t2-cln63_2p0207){ref-type="table"}.[@b21-cln63_2p0207]

Erythrocytes were lysed after staining with BD lysis buffer solution according to the manufacturer's instructions. Data acquisition and analyses were performed on a three-color immunofluorescent FACS with CellQuest 3.1 software (BD).

Injection of BMC During Surgical Myocardial Revascularization
-------------------------------------------------------------

CABG was done during cardiopulmonary bypass and warm blood cardioplegic arrest as previously described.[@b22-cln63_2p0207] Once all bypasses had been completed, 25 samples of cell suspension (0.2 mL) were injected into the ischemic non-bypassable area of myocardium, using a 22-gauge hypodermic needle ([Figure 1](#f1-cln63_2p0207){ref-type="fig"}). Afterwards, the heart was reperfused, and the operation completed as usual.

Statistical Analysis
--------------------

Data analyses were performed with a commercially available statistical package (JMP® for Windows -- version 6.0.0, SAS Institute Inc., Cary, NC). Results for continuous variables are presented as mean±SD, and for categorical variables as percentages. One-way ANOVA with repeated measurements was used for comparison between time points. Statistical significance was set at P\<0.05.

RESULTS
=======

Procedural Data
---------------

The total operation time for CABG (including the intramyocardial injections of BMC) was 6h27min ± 1h25min; the "on-pump" time was 1h04min ± 15min. Patients had 4.1 ± 1.7 coronary arteries with stenosis greater than 70% and they received 2.6 ± 0.2 grafts.

Injected myocardial segments (n=12) included the inferior (n=7), anterior (n=2), septal (n=1), apical (n=1) and lateral (n=1) walls. Note that in two patients, more than one myocardial segment was injected with BMC.

The number of cells injected per patient was 1.3 ± 0.3x10^8^. The fractions of CD34+ and CD133+ cells were 1.50 ± 0.15% and 0.67±0.65%, respectively. A more detailed analysis of the cell population subtypes can be seen in [Table 3](#t3-cln63_2p0207){ref-type="table"}.

Clinical Morbidity and Mortality
--------------------------------

The mean in-hospital stay after surgery was 11 ± 2 days. In-hospital non-fatal complications included pulmonary infection (n=2) and acute decompensation of heart failure (n=1), all of which were managed clinically and completely resolved after a few days. There were no deaths related to the procedure and all patients were discharged for follow-up at the out-patient clinic.

All patients completed the pre-specified first year of follow-up; no complications were recorded. During this period, the angina functional class levels significantly decreased from 3.6 ± 0.8 (baseline) to 1.2 ± 0.4 (12 months) (P \< 0.0001).

Laboratory Tests
----------------

Results of main biochemical/hematological tests are shown in [Table 4](#t4-cln63_2p0207){ref-type="table"}. We observed a significant elevation of C-reactive protein at one month after surgery compared to baseline, but this value returned to the normal range in the following evaluations. No other hematological abnormalities, including liver or renal dysfunction, were observed.

Cardiac Arrhythmias
-------------------

The mean heart rate (HR) and the number of supraventricular or ventricular premature beats are shown in [Table 5](#t5-cln63_2p0207){ref-type="table"}. During follow-up, no patient presented life-threatening arrhythmias such as sustained ventricular tachycardia (VT).

Echocardiogram
--------------

No structural abnormalities were seen on Doppler echocardiograms for any time point after the procedure: no pericardial effusion, no fibrosis at injection sites, and no growth of non-cardiac tissues. At 12 months after surgery, LV function analysis showed that, compared to baseline, there was no significant change in either the mean LV end-systolic volume (73 ± 7 vs. 68 ± 10mL; P=0.41) or the mean end-diastolic volume (149 ± 10 vs. 136 ± 13mL; P=0.47) ([Table 6](#t6-cln63_2p0207){ref-type="table"}). Overall, there was no significant change in the mean LV ejection fraction (0.54 ± 0.03 vs. 0.52 ± 0.03; P=0.68) compared to baseline.

Magnetic Resonance Imaging (MRI)
--------------------------------

As seen in [Figure 2](#f2-cln63_2p0207){ref-type="fig"}, the LV ischemic score decreased significantly during the first year (panel A) as expected after a myocardial revascularization procedure. More interestingly, however, there was also an early and sustained improvement in myocardial perfusion in injected non-revascularized areas compared to baseline (panel B). No structural abnormalities were seen on the MRI after the procedure.

DISCUSSION
==========

The results presented here show the feasibility and long-term safety of intramyocardial injection of autologous BMC combined with surgical myocardial revascularization in patients suffering from diffuse CAD, who were not optimal candidates for a complete surgical bypass procedure. Moreover, injected BMC might have contributed to increased tissue perfusion in areas of ischemic myocardium not suitable for direct revascularization.

The majority of patients with mild to moderate angina can be adequately treated with anti-anginal medications.[@b23-cln63_2p0207] However, as life expectancy increases and the mortality rate due to acute coronary syndromes decreases, there is a growing population of patients with CAD for whom medical therapy is only partially effective. New therapeutic strategies are necessary, since many of them have already undergone multiple PCIs or surgical revascularization and hence, are not "ideal" candidates for additional procedures.

Deprivation of oxygen and nutrients to myocytes in chronic IHD may lead to death of viable myocardium and cell replacement by fibrous tissue deposition, which further impairs LV function. Neoangiogenesis, a multifactorial process involving complex interactions between inflammatory cells, cytokines, and many extracellular matrix proteins, is a crucial step in preserving cardiomyocytes from death.[@b24-cln63_2p0207] Usually, when extensive myocardial ischemic injury occurs, the contribution of neoangiogenesis to the ischemic capillary network is insufficient to keep pace with tissue demands; therefore, normal contractility of ischemic, but viable, myocardium cannot be sustained.[@b25-cln63_2p0207]

Experimental evidence suggests that BMC have the potential to induce therapeutic angiogenesis in ischemic tissues.[@b26-cln63_2p0207] After vascular injury, endothelial progenitor cells are naturally mobilized from the bone marrow to the circulation, along with hematopoietic stem cells and hematopoietic progenitor cells. The physiological role of co-recruitment of hematopoietic stem and progenitor cells in formation of long-lasting functional neovessels remains to be determined.[@b27-cln63_2p0207]

Based on the initial reports of successful transplantation of progenitor cells in patients with acute or chronic coronary artery disease,[@b9-cln63_2p0207]--[@b11-cln63_2p0207] we conducted this phase I, open-label, non-randomized trial and were able to show that intramyocardial injection of autologous BMC combined with surgical myocardial revascularization is feasible, safe and well-tolerated. However, our data suggest a role for injected BMC in increasing myocardial perfusion.

Regarding safety issues within the first year after this procedure, early complications included pulmonary infection and decompensation of heart failure, conditions most likely related to the surgical procedure itself rather than the cell injections *per se*. One of the most disturbing complications related to cell therapy, based on previous experience with myoblasts, is the occurrence of malignant arrhythmias. Fortunately, there was no detectable increase in the number of supraventricular or ventricular premature beats and no life-threatening arrhythmias were detected.

Except for a transient elevation of C-reactive protein early in the follow-up after surgery, all other biochemical and hematological values were within the normal range. Again, since CRP is a marker of inflammation, its elevation is no surprise after a major surgery like CABG. Cardiac imaging studies showed no evidence of scar tissue formation in the injection sites, no evidence of structural abnormalities related to the procedure such as pericardial effusion, and no evidence of *in situ* growth of non-cardiac tissues.

Overall, there was no overall appreciable change in LV ejection fraction or end-diastolic/systolic volumes. One can assume that since the mean LV function was within the normal range, no significant improvement would be seen in an already normal LV function. Nevertheless, specifically in patients with low LV ejection fraction, LV function increased significantly after surgery (data not shown), reflecting the functional recovery of ischemic viable (hibernating) myocardium.

Although this was basically a safety trial, we performed a myocardial perfusion assessment in an attempt to collect preliminary data on the efficacy of stem cell therapy for severe CAD. MRI results showed a significant decrease in the LV ischemic score after the procedure; this decrease was not only in the total ischemic score (as expected), but also in the injected, non-revascularized areas. These data suggest an improvement in myocardial perfusion in the injected but non-grafted areas. Even though an indirect effect for this improvement from the grafts placed in the adjacent areas cannot be ruled out, it is tempting to speculate that the transplanted cells may have contributed to this response. In a study similar to ours, Stamm et al.[@b28-cln63_2p0207] injected BMC into the infarct border zone in six patients who had had a myocardial infarction and undergone CABG. Their work showed that, as of three to nine months after surgery, LV function was enhanced in four patients, and infarct tissue perfusion had improved strikingly in five patients. More recently,[@b29-cln63_2p0207] the same group extended their initial series of patients and concluded that, at least for the first three years of follow-up, intramyocardial delivery of purified bone marrow stem cells together with CABG surgery is safe and provides beneficial effects.

In summary, we were able to show that, during the first year of a four year follow-up, intramyocardial injection of BMC appears to be safe and may have contributed to increased myocardial perfusion in the ischemic, nonrevascularized myocardium. The effectiveness of cell transplantation in improving myocardial perfusion and contractility in patients with advanced CAD is a question to be addressed in controlled, randomized studies with a larger series of patients and longer follow-up. Cell transplantation has been addressed in recent studies, albeit with conflicting results.[@b30-cln63_2p0207],[@b31-cln63_2p0207] A much larger, multicenter, randomized, double-blind, placebo-controlled study is underway.[@b32-cln63_2p0207]
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###### 

Clinical characteristics of enrolled patients.

  Variable                                               Patients (n=10)
  ------------------------------------------------------ -----------------
  Age (years)                                            59±5
  Male /female (n)                                       8 /2
  Diabetes (n)                                           7
  Hypertension (n)                                       10
  Hypercholesterolemia (n)                               8
  Current or previous smoker (n)                         6
  Previous myocardial infarction (n)                     5
  Previous myocardial revascularization (PCI/CABG) (n)   7

###### 

Flow cytometry markers.[@b21-cln63_2p0207]

  Antibody                   Main cellular expression                                                                                              Manufacturer
  -------------------------- --------------------------------------------------------------------------------------------------------------------- ------------------------
  Anti-CD3 (clone HI3a)      Thymocytes, T cells                                                                                                   Pharmingen
  Anti-CD4 (clone MT310)     Thymocyte subsets, helper and inflammatory T cells (about two thirds of peripheral T cells), monocytes, macrophages   Pharmingen
  Anti-CD8 (clone DK250      Thymocyte subsets, cytotoxic T cells (about one third of peripheral T cells)                                          Pharmingen
  Anti-CD10 (clone HI10a)    B and T cell precursors, bone marrow stromal cells                                                                    Becton, Dickinson & Co
  Anti-CD13 (clone WM-47)    Myelomonocytic cells                                                                                                  Dako North America
  Anti-CD14 (clone TUK-4)    Myelomonocytic cells                                                                                                  Pharmingen
  Anti-CD15 (clone BI59)     Neutrophils, eosinophils, monocytes                                                                                   Pharmingen
  Anti-CD19 (clone HD-37)    B cells                                                                                                               Pharmingen
  Anti-CD31 (clone L133.1)   Monocytes, platelets, granulocytes, B cells, endothelial cells                                                        Becton, Dickinson & Co
  Anti-CD34 (clone HPCA-2)   Hematopoietic precursors, capillary endothelium                                                                       Becton, Dickinson & Co
  Anti-CD38 (clone HB27)     Early B and T cells, activated T cells, germinal center B cells, plasma cells                                         Becton, Dickinson & Co
  Anti-CD45 (clone 2D1)      All hematopoietic cells                                                                                               Becton, Dickinson & Co
  Anti-CD56 (clone BI59)     Natural killer cells                                                                                                  Pharmingen
  Anti-CD133 (clone AC141)   Stem/progenitor cells                                                                                                 Miltenyi Biotech Inc

###### 

Selected cell populations (%) after flow cytometry.

  Cell Population Phenotype   \% of Injected Cells
  --------------------------- ----------------------
  CD34+                       1.50±0.15
  CD45+ CD133+                0.7±0.1
  CD45- CD133+                0.04±0.01
  CD14+                       6.6±0.8
  CD19+                       4.0±0.5
  CD4+                        9.1±1.1
  CD8+                        5.7±0.7
  CD31+                       2.2±0.3

###### 

Selected laboratory tests at baseline and during the first year of follow-up.

  Variable                     Baseline   1 m        3 m        6 m        12 m       P
  ---------------------------- ---------- ---------- ---------- ---------- ---------- ------
  Hemoglobin (g/dL)            13.9±1.5   12.0±1.3   13.6±1.3   13.4±2.1   13.2±1.9   0.12
  White cells (x10^3^/mm^3^)   7.6±1.9    7.0±1.7    7.1±2.3    6.7±1.5    6.5±1.6    0.67
  Platelets (x10^3^/mm^3^)     230±57     271±144    231±46     236±79     191±78     0.39
  Urea (mg/dL)                 42±14      44±12      37±13      39±15      44±13      0.80
  Creatinine (mg/dL)           1.2±0.3    1.2±0.6    1.1±0.2    1.2±0.5    1.2±0.5    0.92
  AST                          12±6       10±4       10±2       10±3       10±3       0.55
  ALT                          16±11      19±5       11±2       11±5       11±4       0.44
  Glucose level (mg/dL)        113±34     124±39     113±19     111±29     137±48     0.43
  Total cholesterol (mg/dL)    184±36     154±29     165±27     177±32     167±29     0.25
  HDL-cholesterol (mg/dL)      43±7       37±5       40±5       40±5       45±6       0.02
  LDL-cholesterol (mg/dL)      106±24     84±24      93±29      92±38      93±21      0.57
  Triglycerides (mg/dL)        178±89     167±58     157±51     179±65     133±46     0.47
  C-reactive protein (mg/dL)   0.1±0.1    4.0±3.5    0.2±0.1    0.2±0.1    0.4±0.5    0.01
  INR                          1.0±0.1    1.1±0.1    1.1±0.1    1.0±0.1    1.0±0.1    0.80

###### 

Data from 24-h ECG monitoring (Holter) at baseline and during the first year of follow-up.

  Variable                             Baseline   1 m     3 m     6m      12m     P
  ------------------------------------ ---------- ------- ------- ------- ------- ------
  Mean heart rate (bpm/min)            73±10      75±12   79±17   74±11   74±12   0.88
  Ventricular premature beats/h        6±13       5±9     8±17    34±6    6±9     0.58
  Supraventricular premature beats/h   3±4        7±11    2±2     4±9     15±35   0.55

###### 

Echocardiography data at baseline and during the first year of follow-up.

  Variable                         Baseline   1 m    3 m     6m     12m     P
  -------------------------------- ---------- ------ ------- ------ ------- ------
  Septum (mm)                      10±1       10±1   10±1    10±1   9±2     0.28
  Posterior wall (mm)              10±1       9±1    10±1    10±1   9±1     0.39
  LV end-diastolic diameter (mm)   51±7       55±6   53±5    53±5   53±9    0.94
  LV ejection fraction (%)         63±14      66±8   58±13   61±8   67±13   0.80
  Left atrium (mm)                 41±8       40±3   40±2    42±1   38±5    0.62
  Aorta (mm)                       32±3       32±3   32±4    32±3   28±9    0.58
